Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.57 |
| ▸ | HRH2 | P25021 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650373 | 0.85 | HRH4 (0.52) | HRH4HRH3HRH2EEF2KHRH1 | |
| SCHEMBL13650348 | 0.82 | HRH4 (0.59) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650364 | 0.82 | HRH4 (0.63) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650617 | 0.82 | HRH4 (0.58) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650370 | 0.81 | HRH4 (0.60) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650366 | 0.81 | HRH4 (0.60) | HRH4HRH3HRH2CHRNB2CHRNB4 | |
| SCHEMBL13650383 | 0.81 | HRH4 (0.60) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650645 | 0.80 | HRH4 (0.56) | HRH4HRH3HRH2DRD2HRH1 | |
| SCHEMBL13650331 | 0.80 | HRH4 (0.59) | HRH4HRH3HRH2EEF2KKDM4E | |
| SCHEMBL13650341 | 0.80 | HRH4 (0.59) | HRH4HRH3HRH2DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | HRH4 3370/4885HRH3 3555/4885HRH2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.